Answers are grounded in this paper and cite their sources.
Retrospective cohort study demonstrates higher 12-week wound healing with nanosilver in diabetic foot ulcer patients, indicating superior closure rates compared to alginate dressings.
Diabetic foot ulcers (DFUs) are associated with prolonged morbidity and limb-related complications. This single-center retrospective cohort study compared nanosilver and alginate primary dressing strategies in patients managed within a multidisciplinary diabetic-foot program between January 2020 and December 2023. Among 393 screened patients, 361 formed the unmatched cohort, including 121 treated with nanosilver and 240 with alginate dressings; 1:1 propensity-score matching generated 115 matched pairs. The single primary endpoint was complete wound healing at week 12. Healing occurred in 87 of 115 patients (75.7%) receiving nanosilver and 65 of 115 (56.5%) receiving alginate dressings (matched OR, 2.47; 95% CI, 1.32-4.84; P = 0.003; matched RR, 1.34; 95% CI, 1.11-1.62). At least 50% wound-area reduction at week 4 occurred in 82.6% versus 67.0% (matched OR, 2.80; 95% CI, 1.32-6.46; Holm-adjusted P = 0.015), and median time to complete healing was 45 versus 58 days (HR, 1.58; 95% CI, 1.22-2.05; Holm-adjusted P < 0.004). The primary association remained similar in the extended measured-confounding sensitivity analysis (adjusted OR, 2.31; 95% CI, 1.17-4.56). Other clinical and safety outcomes were exploratory. Nanosilver dressing use was associated with greater 12-week complete healing and shorter time to closure in this matched tertiary-care cohort; prospective multicenter validation is required.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: